September 18, 2025Revista Portuguesa de CardiologiaOpen Access

Dapagliflozin Alleviates Isoprenaline-Induced Cardiac Hypertrophy by Promoting Mitophagy via AMPKα2 Signaling Pathway

View Full Paper

Ask AI

Bookmark

Dapagliflozin significantly reduces isoprenaline-induced cardiac hypertrophy in H9c2 cells.
Isoprenaline treatment notably decreased AMPKα2 expression, while dapagliflozin increased it.
Mitophagy activation through AMPKα2 signaling is crucial for preventing mitochondrial damage in heart failure.
Dapagliflozin's protective effects may enable new therapeutic strategies for heart failure.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This research demonstrates how dapagliflozin reduces cardiac hypertrophy via the AMPKα2 pathway, highlighting its potential in heart failure treatment.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/68d433b0713b0b5dfea734c3 https://doi.org/10.1016/j.repc.2025.05.008

View Full Paper

Ask AI

Bookmark

Implication

This research demonstrates how dapagliflozin reduces cardiac hypertrophy via the AMPKα2 pathway, highlighting its potential in heart failure treatment.

Dapagliflozin Alleviates Isoprenaline-Induced Cardiac Hypertrophy by Promoting Mitophagy via AMPKα2 Signaling Pathway

Key Points

Discussion

Implication

Cite This Study

Dapagliflozin Alleviates Isoprenaline-Induced Cardiac Hypertrophy by Promoting Mitophagy via AMPKα2 Signaling Pathway

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading